InvestSMART

Tryptamine Therapeutics Limited (ASX:TYP)

ALERT: Price-sensitive ASX Announcement for TYP
Current share price for TYP : $0.034 -0.002 (-5.56%)+
Announcement
Release
18 Nov 2025 8:55AM
Price at Release
$0.036
Full Release
download
Summary
Tryptamine Therapeutics Limited ('Tryp') has made significant progress in its clinical trial for treating Binge Eating Disorder (BED) with its proprietary formulation TRP-8803. The trial has currently enrolled a second patient, with initial patient dosing scheduled for 1 December 2025. This trial, conducted in collaboration with Swinburne University, is notable for being the first clinical evaluation of TRP-8803 in a BED population. Two cohorts will receive doses of TRP-8803, accompanied by supportive therapy, with results expected in Q1 2026. The Butterfly Foundation is aiding enrollment by raising awareness and connecting with potential candidates. This initiative is part of Tryp's broader strategy to develop safe, evidence-based treatments for BED using psychedelic-assisted therapy.
Key Points
  • Second patient enrolled in TRP-8803 trial for BED.
  • First patient dosing scheduled for 1 December 2025.
  • TRP-8803 is an IV-infused psilocin formulation.
  • Trial aims to evaluate TRP-8803 in BED population.
  • Butterfly Foundation supports patient recruitment.
  • Initial results expected in Q1 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.